POA Pharma Scandinavia AB, a Galen Limited owned company, has announced its entry into the German market, securing an exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose OGS.

POA Pharma’s parent company, Galen Limited, a global pharmaceutical company, and proud member of the Almac Group, has an existing, long standing in-licensing relationship with Penlan for Rapilose OGTT in the UK and Ireland.  This agreement marks the first time Rapilose has been available in Germany. 

CEO of POA Pharma, Dr Dennise Broderick said: “We are delighted to enter the German market, via POA Pharma and Penlan Healthcare’s new in-licensing agreement. Expansion into this territory has been high on our agenda and further highlights our commitment to continually invest in new territories and therapeutic areas through both partnerships and acquisitions.”

In January 2020, the multi-million-pound acquisition and takeover of the boutique healthcare company POA Pharma was completed, strengthening access to the Nordic region and adding considerable global reach.

Simon Lawrence, Commercial Director of POA Pharma, who will be managing the expansion into Germany, said: “We have long been recognised as a partner of choice for specialty pharma companies to launch and promote their products within the UK and Ireland. Our acquisition of POA Pharma further developed this position in the Nordics, and provided us with the springboard for expansion into other Northern European markets, with expertise in several therapeutic areas, including Acute Care (anaesthesiology/emergency medicine), Otolaryngology (ENT) and Medical Nutrition.

"Our long heritage and significant experience in delivering valued medicines to the people that need them most, coupled with POA Pharma’s important portfolio, means we have the opportunity to help more patients affected by a variety of diseases within Europe, and indeed on a truly global scale."

The latest addition to this portfolio, Rapilose OGS, is a ready-to-use glucose solution designed for the dietary management of disease-related malnutrition and malabsorption states or other conditions requiring intake of high or rapidly available carbohydrate supplements, as an energy source for patients with inadequate energy intake or increased energy needs.  Each 300ml pouch delivers exactly 75g anhydrous glucose. 

#ENDS#